EUVIMEDEUVIMED entdecken
Crossref

Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination With Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies (mAbs) in KRAS G12D–Mutated Colorectal Cancer (CRC) Models

J. Teh, C. Kuhlberg, P. Hegan, K.D. Smith, J. Pizzano, E. Masson, X. Wang

European Journal of Cancer · 2026-11 · 248 · 117698

DOI: 10.1016/j.ejca.2026.117698 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von J. Teh und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Teh, J., Kuhlberg, C., Hegan, P., Smith, K., Pizzano, J., Masson, E., & Wang, X. (2026). Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination With Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies (mAbs) in KRAS G12D–Mutated Colorectal Cancer (CRC) Models. European Journal of Cancer, 248, 117698. https://doi.org/10.1016/j.ejca.2026.117698

Vancouver

Teh J, Kuhlberg C, Hegan P, Smith K, Pizzano J, Masson E, et al. Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination With Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies (mAbs) in KRAS G12D–Mutated Colorectal Cancer (CRC) Models. European Journal of Cancer. 2026;248:117698. doi:10.1016/j.ejca.2026.117698

BibTeX
@article{Teh2026,
  author = {Teh, J. and Kuhlberg, C. and Hegan, P. and Smith, K.D. and Pizzano, J. and Masson, E. and Wang, X.},
  title = {Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination With Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies (mAbs) in KRAS G12D–Mutated Colorectal Cancer (CRC) Models},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {248},
  pages = {117698},
  doi = {10.1016/j.ejca.2026.117698}
}
Kostenlos starten →